Core Insights - Bioventus Inc. reported strong financial results for Q4 and full-year 2024, indicating a transformational year for the company with expectations for continued growth in 2025 [2][3][6] Financial Performance - Q4 2024 worldwide revenue reached $153.6 million, a 13.5% increase year-over-year, driven by growth in Pain Treatments and Surgical Solutions [3][10] - Full-year 2024 revenue totaled $573.3 million, an 11.9% increase compared to 2023, with organic growth of 14.4% [6][12] - Adjusted EBITDA for Q4 2024 was $28.3 million, up 28.3% from $22.0 million in the previous year, attributed to revenue growth and margin expansion [4][10] - The company reported a net loss from continuing operations of $0.3 million in Q4 2024, significantly improved from a loss of $7.7 million in Q4 2023 [4][5] Revenue Breakdown - In Q4 2024, U.S. Pain Treatments generated $62.8 million, an 18.7% increase, while Surgical Solutions saw a 16.8% increase to $46.4 million [9] - For the full year, U.S. Pain Treatments revenue was $234.9 million, up 18.7%, and Surgical Solutions revenue was $167.7 million, an 18.2% increase [12] Strategic Initiatives - The company divested its Advanced Rehabilitation Business in Q4 2024, receiving $24.7 million in proceeds, which is expected to enhance focus on core growth areas [14] - Bioventus aims to achieve net sales of $560 million to $570 million in 2025, reflecting organic growth of approximately 6.1% to 8.0% [13][22] Operational Highlights - The company achieved five consecutive quarters of double-digit revenue growth in Pain Treatments and Surgical Solutions [14] - Cash from operations in Q4 2024 was $19.3 million, an increase of 86.3% compared to the previous year [10][28]
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results